Street Analysts View On Akcea Therapeutics, Inc. (AKCA), Theravance Biopharma, Inc. (TBPH)

Akcea Therapeutics, Inc. (NASDAQ:AKCA) notched a 0.22% intraday gain moving at $18.43. When the opening bell rang, the price was $18.49. The number of shares that were traded during the day was 0.33 million, which corresponds to its 3-month volume average of 0.41 million shares a day.

Akcea Therapeutics, Inc. (AKCA) Analyst Opinion

Akcea Therapeutics, Inc. has a consensus buy rating from 4 Wall Street analysts, and the number of shares currently sold short amount to at least 21.92% of shares outstanding. The stock sank -4.9% last month and is up 94.41 this year. Wall Street is only getting more bullish on the stock, with 4 of analysts who cover AKCA having a buy-equivalent rating. Analysts have placed a $24 price target on Akcea Therapeutics, Inc., suggesting a 30.22% gain from recent close. It’s currently trading about -40.99% below its 52-week high.

Akcea Therapeutics, Inc. (NASDAQ:AKCA) Intraday View

This stock (AKCA) is ahead of its 52-week low with 127.53%. Its last month’s stock price volatility remained 4.89% which for the week stands at 7.84%. The share price has moved forward from its 20 days moving average, trading at a distance of 4.63% and stays -15.57% away from its 50 days moving average. Over the last five days, shares have managed 6.59% gains and now is down -4.17% since hitting its 200-day moving average of $18.12. Akcea Therapeutics, Inc. (AKCA) has made its way to a 12-month decline of 0%.

Turning to Theravance Biopharma, Inc. (NASDAQ:TBPH), its shares were trading at $28.24 a retreat of $-0.3, on the trading floor. The stock, after opening at $28.41, touched a high of $28.6 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.9. Theravance Biopharma, Inc. has 1 buy ratings, 0 holds and 1 sells even after the stock tumbled -34.99% from its high of $43.44 to a $1.48 billion market value through last close.

Theravance Biopharma, Inc. (TBPH) Consensus Price Target

The company’s consensus rating on Reuter’s scale improved from 2.67 to 2.86 during a month. Analysts set a 12-month price target of $38.33 a share. The target implies a 35.73% spike from where the shares are currently trading. Also, the current price highlights a discount of 94.76% to analysts’ high consensus price target.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Intraday Trading

The counter witnessed a trading volume of 0.23 million shares versus an average volume of 0.19 million shares during last trading session. Its last month’s stock price volatility remained 4.89% which for the week approaches 4.49%. The lowest price the stock reached in the last trading day was $28 and compares with the $23.15 52-week low. The stock recovered 21.97% since its low point and has performed -11.42% year-to-date.

Previous articleAnalyst Recommendations And Earnings Forecast: KEMET Corporation (KEM), The Finish Line, Inc. (FINL)
Next articleAnalyst Commentary On Antares Pharma, Inc. (ATRS), Approach Resources, Inc. (AREX)